Compass Therapeutics' Series A - II Round

Compass Therapeutics raised a round of funding on January 08, 2016. Investors include Zymeworks.

Compass Therapeutics, formerly Kairos Biologics Foundation, is comprehensively drugging the tumor-immune synapse with human antibodies against cell surfaces and soluble targets.…

Articles about Compass Therapeutics' Series A - II Round: